Shots: Ligand will acquire Ab Initio for $12M in cash as Ab Initio’s antigen technology is complimenting Ligand’s OmniAb therapeutic antibody discovery platform which will further strengthen and expand ligand’s […]readmore
Tags : Antigen Technology